Quanta Fluid Solutions Ltd Appoints New Chief Executive Officer.

Alcester, Warwickshire, UK, 8 January 2014: Seroba Kernel investee company, Quanta Fluid Solutions Ltd, a pioneering medical devices company that is developing advanced haemodialysis systems for patient self-care and dialysis centres, today announces the appointment of John E. Milad as Chief Executive Officer.

John’s career spans twenty years, with extensive experience leading and working with international healthcare companies as an executive manager, board member, private equity investor and corporate financier, with a strong focus on emerging medical technologies. Leading up to his appointment, John served as a Non-Executive Director to Quanta for four years following the initial investment in the company he led at NBGI Ventures (“NBGI”), a leading venture capital fund investing in medical technology companies.

As an Investment Director at NBGI, John was also closely involved — both as a board member and a venture investor — with a number of other innovative medtech companies such as Cellnovo Ltd (UK), Symetis SA (Switzerland), Advanced Cardiac Therapeutics Inc (US), and BoneSupport (Sweden). In this role, John was involved in a range of finance, strategy, business development and operational matters, guiding these emerging companies through regulatory approvals and commercialisation for new medical products. John is a graduate of the University of Chicago. He currently sits on the i4i selection panel for the NHS National Institute for Health Research and is a regular speaker and panellist at various global medtech and investment conferences, including the Economist Pharma Summit in London in 2014.

Commenting upon his appointment as Chief Executive Office of Quanta, John E. Milad said: “I am delighted to lead Quanta as the Company enters its next phase of development, when we will soon obtain CE Mark and then commence market introduction for our first product. The forthcoming year promises to be one of great strategic and operational importance, as we initiate the clinical launch of our unique high-performance, portable, cartridge-based dialysis system.

I am particularly excited about the path ahead for Quanta. Our technology shows great promise to help millions of renal patients around the world to enjoy a better quality of life by enabling and supporting a broad range of dialysis modalities across the full continuum of care, from the clinic to the home.”

Johan de Ruiter, Chairman of Quanta, added: “The Board is delighted to welcome John as Quanta’s new CEO. We have known John for many years as a Director of the Company and, as a healthcare expert, he has been instrumental in helping us to develop Quanta operationally and strategically. John has valuable experience with commercialisation of innovative medical devices and I am therefore extremely confident that he will lead Quanta towards delivering significant benefits to patients, healthcare providers and payors across the globe.”

“I would also like to thank Martin Johnson, our departing CEO and founder, for all the hard work and dedication he has shown to Quanta. His original idea and engineering skills have led to a break-through innovation in dialysis. We look forward to being able to continue to use his expertise and support as the company transitions to its next phase.”


For further information, please contact:
Vicky La Touche-Price
Seroba Kernel Life Sciences
+353 1 6334028

< back to home page